Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2024-2032

Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A5575
Buy Now

Market Overview:

The global hereditary angioedema therapeutic market size reached US$ 2.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.18% during 2024-2032.

Report Attribute
 Key Statistics 
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 2.9 Billion
Market Forecast in 2032
US$ 5.5 Billion
Market Growth Rate 2024-2032 7.18%


Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to a deficiency of a blood protein. It also leads to fluid leakage due to the constant accumulation of liquids outside the veins of hands, feet, intestinal wall, genitals, face, tongue, and larynx. At present, there is a rise in the demand for hereditary angioedema therapeutics due to the growing advancements in novel therapeutics across the globe.

Hereditary Angioedema Therapeutic Market

Hereditary Angioedema Therapeutic Market Trends:

There is presently a considerable increase in the prevalence of HAE among individuals due to a lack of C1 protein. As a result, there is a rise in the demand for HAE therapeutics around the world. This, along with the growing awareness among the masses about the treatment of HAE, represents one of the key factors driving the market. Moreover, key market players are extensively investing in research and development (R&D) activities to enhance orphan drug development. This, coupled with the escalating demand for subcutaneous injections that are highly effective in administering medications, such as insulin, morphine, diacetylmorphine and goserelin, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to facilitate faster diagnosis and provide optimal standards of treatment and care to patients. In line with this, rising incidences of genetic mutations leading to the disorder are positively influencing the market. Besides this, the escalating demand for preventive medical care to avoid future illness and treatment is offering lucrative growth opportunities to industry investors. Apart from this, the burgeoning healthcare industry is bolstering the growth of the market.

 

 
 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hereditary angioedema therapeutic market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug class, treatment type, route of administration and end user.

Breakup by Type:

 

 
 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Type I Hereditary Angioedema
  • Type II Hereditary Angioedema
  • Type III Hereditary Angioedema
     

Breakup by Drug Class:

  • C1-Esterase Inhibitor
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others
     

Breakup by Treatment Type:

  • Prophylaxis Treatment
  • On-demand Treatment
     

Breakup by Route of Administration:

  • Intravenous
  • Subcutaneous
  • Oral
     

Breakup by End User:

  • Hospitals
  • Clinics
  • Home Healthcare
  • Others
     

Breakup by Region:

 

 
 

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Type, Drug Class, Treatment Type, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

We expect the global hereditary angioedema therapeutic market to exhibit a CAGR of 7.18% during 2024-2032.

The high prevalence of HAE among individuals owing to the lack of C1 protein, coupled with the growing cases of genetic mutations, are primarily driving the global hereditary angioedema therapeutic market.

The sudden outbreak of the COVID-19 pandemic had led to postponement of elective hereditary angioedema treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for hereditary angioedema therapeutics.

Based on the type, the global hereditary angioedema therapeutic market can be divided into type I hereditary angioedema, type II hereditary angioedema, and type III hereditary angioedema. Currently, type I hereditary angioedema holds the majority of the global market share.

Based on the drug class, the global hereditary angioedema therapeutic market has been segregated into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Among these, C1-esterase inhibitor currently accounts for the largest market share.

Based on the treatment type, the global hereditary angioedema therapeutic market can be categorized into prophylaxis treatment and on-demand treatment. Currently, on-demand treatment exhibits a clear dominance in the market.

Based on the route of administration, the global hereditary angioedema therapeutic market has been segmented into intravenous, subcutaneous, and oral, where intravenous currently accounts for the largest market share.

Based on the end user, the global hereditary angioedema therapeutic market can be bifurcated into hospitals, clinics, home healthcare, and others. Currently, hospitals hold the majority of the total market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global hereditary angioedema therapeutic market include Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More